Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin.
Mulla
N
N
Section of Pediatric Cardiology, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit 48201, USA.
Karpawich
P P
PP
D000241:Adenosine / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000075202:Contraindications; D004077:Digoxin / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D007231:Infant, Newborn; D013617:Tachycardia, Supraventricular / Q000139:chemically induced / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000139:chemically induced*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents; D004077:Digoxin; D000241:Adenosine